US Patent Issued for Exactech’s Predict+™, First Machine Learning-Based Software that Informs Surgeons with Patient-Specific Outcome Predictions after Shoulder Replacement Surgery

Predict+ Expands Exactech’s Active Intelligence® Portfolio of Smart Solutions

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today that it has been granted patent #11,490,966 by the United States Patent and Trademark Office.

This newly issued patent describes a method and system to predict outcomes following arthroplasty procedures and relates to Predict+. Predict+ is a data-driven, clinical decision support tool and the first software of its kind to use machine learning to predict individual patient outcomes after shoulder replacement surgery. The software was released in November 2020 and was designed to better inform surgeons regarding the expected outcomes that can be achieved after shoulder arthroplasty, based on the clinical experience documented within the world’s largest single-shoulder prosthesis outcomes database, consisting of more than 15,000 patients.

“Predict+ is a novel application of orthopedic clinical research and data science and represents a significant, value-creating advancement to the surgeon-patient preoperative consultation process related to shoulder arthroplasty,” said Chris Roche, Exactech’s Senior Vice President of Extremities. “This granted patent strengthens Exactech’s leadership position in the orthopedic applications of artificial intelligence and features several broad claims which cover future innovations and expands Exactech’s intellectual property portfolio.”

With Predict+, the surgeon inputs as few as 19 data points about a patient and within seconds, the software predicts the patient’s potential outcomes, including pain, function, and range of motion. In addition, it compares predictive results for anatomic and reverse shoulder arthroplasty at multiple post-operative timepoints. This guidance can help the surgeon better personalize patient treatment by identifying factors that drive the outcome predictions, including modifiable factors such as the patient losing weight, quitting smoking, and completing pre-habilitation. Finally, Predict+ aggregates the outcomes and complications within the database so that surgeons and patients can compare their personalized predictions with the clinical experience of patients of similar age and gender after anatomic and reverse shoulder replacement.

“Developed in partnership with Advata, Predict+ showcases the predictive power of machine learning to transform healthcare,” said Vikas Kumar, Advata’s Vice President of Research and Machine Learning. “Predict+ delivers personalized, evidence-based predictions that objectively quantify the risk and benefit that an individual patient may experience after anatomic and reverse shoulder replacement, aligning patient and surgeon expectations for shared decision making.”

Predict+ is built upon previously published, peer-reviewed research and is the latest in a fast-growing line-up of technologies that power Exactech’s Active Intelligence platform. Predict+ supports Exactech’s Equinoxe® shoulder, the industry’s fastest growing and most studied shoulder system. It is accessible through the Equinoxe Planning App preoperative planning software, which can be used with the ExactechGPS® navigation system in the operating room, connecting the preoperative plan with implant placement.

Predict+ is available to surgeons globally on a limited basis. Please contact your Exactech representative for additional information.

SourceExactech
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy